Cuál es el precio por AbbVie Inc. (ABBV)

Precio por AbbVie Inc. (ABBV) es de$263.25

Cuál es la capitalización de mercado por AbbVie Inc. (ABBV)

Capitalización de mercado por AbbVie Inc. (ABBV) es $465.10B

AbbVie Inc. (ABBV) Dividendos

AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.

Año	Dividendo (ajustado por splits de acciones)	Cambiar
2026 (TTM)	$1.73	-73.63%
2025	$6.56	5.81%
2024	$6.20	4.73%
2023	$5.92	4.96%
2022	$5.64	8.46%
2021	$5.20	10.17%
2020	$4.72	10.28%
2019	$4.28	19.22%
2018	$3.59	40.23%
2017	$2.56	12.28%
2016	$2.28	12.87%
2015	$2.02	21.69%
2014	$1.66	3.75%
2013	$1.60	0.00%

Año

Dividendo (ajustado por splits de acciones)

Cambiar

2026 (TTM)

$1.73

-73.63%

2025

$6.56

5.81%

2024

$6.20

4.73%

2023

$5.92

4.96%

2022

$5.64

8.46%

2021

$5.20

10.17%

2020

$4.72

10.28%

2019

$4.28

19.22%

2018

$3.59

40.23%

2017

$2.56

12.28%

2016

$2.28

12.87%

2015

$2.02

21.69%

2014

$1.66

3.75%

2013

$1.60

0.00%

Año	Dividendo	Cambiar
2026 (TTM)	$1.73	-73.63%
2025	$6.56	5.81%
2024	$6.20	4.73%
2023	$5.92	4.96%
2022	$5.64	8.46%
2021	$5.20	10.17%
2020	$4.72	10.28%
2019	$4.28	19.22%
2018	$3.59	40.23%
2017	$2.56	12.28%
2016	$2.28	12.87%
2015	$2.02	21.69%
2014	$1.66	3.75%
2013	$1.60	0.00%

Año

Dividendo